Renowned experts challenge conventional wisdom across the imaging community
A special issue of the
Journal of the American College of Radiology (JACR), published by Elsevier, challenges conventional wisdom across the imaging community.
This collection of articles, the Provocative Issue, presents extreme opinions on pressing issues confronting radiologists with the deliberate aim of sparking positive dialog and debate that will lead to innovative solutions to improve patient care and imaging-related outcomes.
The issue is guest-edited by:
Caroline Chung, MD, MSc, Director of Advanced Imaging - Strategic Initiative and Director of Imaging Technology and Innovation, Department of Radiation Oncology and Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;
Loading video.
VIDEO: JACR Deputy Editor-in-Chief Christoph I. Lee, MD, MS, and guest editor Reed A. Omary, MD, MS, discuss the JACR provocative special issue. view more
Credit: Journal of the American College of Radiology
Philadelphia, January 12, 2021 - A special issue of the
Journal of the American College of Radiology (JACR), published by Elsevier, challenges conventional wisdom across the imaging community. This collection of articles, the Provocative Issue, presents extreme opinions on pressing issues confronting radiologists with the deliberate aim of sparking positive dialog and debate that will lead to innovative solutions to improve patient care and imaging-related outcomes.
The issue is guest-edited by:
(1)
- Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging -
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced that the first patient has been dosed in its Phase 3 REVELATE clinical trial of
18F-fluciclovine, a positron emission tomography (PET) imaging radiopharmaceutical being studied for potential use in detecting recurrent brain metastases. The REVELATE study is a Phase 3, multi-center, single-arm imaging study being conducted in the United States. Its purpose is to assess the diagnostic performance of
18F-fluciclovine PET in detecting recurrent brain metastases in patients previously treated with radiation therapy. The first patient dosed in the study was at Yale University, New Haven, Conn., under the auspices of Dr. Mariam Aboian, Assistant Professor of Radiology.
Virtual care during COVID-19 delivers impressive benefits for cancer patients, clinicians
Patients and healthcare providers at the Princess Margaret Cancer Centre rated virtual care during COVID-19 as highly satisfactory overall for quality of care and convenience, while at the same time-saving patients millions in costs.
Research led by Princess Margaret Radiation Oncologist Dr. Alejandro Berlin showed that virtual care can be implemented rapidly and safely across a highly-specialized and high-volume cancer center. Eighty (80) percent of patients reported they were either very satisfied or satisfied with it, citing convenience as the main factor, with 72 percent of physicians reporting similar satisfaction with it.
Getting control of COVID-19 will take more than widespread vaccination; it will also require a better understanding of why the disease causes no apparent symptoms in some people but leads to rapid multi-organ failure and death in others, as well as better insight into what treatments work best and for which patients.